Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 4
2006 7
2007 8
2008 18
2009 19
2010 13
2011 21
2012 20
2013 21
2014 24
2015 17
2016 24
2017 23
2018 28
2019 26
2020 24
Text availability
Article attribute
Article type
Publication date

Search Results

269 results
Results by year
Filters applied: . Clear all
Page 1
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750. N Engl J Med. 2019. PMID: 31553833 Clinical Trial.
BACKGROUND: The efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as induction and maintenance therapy in patients with ulcerative colitis is unknown. METHODS: We evaluated ustekinumab as 8-week indu …
BACKGROUND: The efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as indu …
Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases.
Bunte K, Beikler T. Bunte K, et al. Int J Mol Sci. 2019 Jul 10;20(14):3394. doi: 10.3390/ijms20143394. Int J Mol Sci. 2019. PMID: 31295952 Free PMC article. Review.
In addition, Th17 cells, their key cytokine IL-17, and IL-23 seem to play pivotal roles. This review aims to provide an overview of the current knowledge about the differentiation of Th17 cells and the role of the IL-17/IL-23 axis in the …
In addition, Th17 cells, their key cytokine IL-17, and IL-23 seem to play pivotal roles. This review aims to provide an …
IL-23 in inflammatory bowel diseases and colon cancer.
Neurath MF. Neurath MF. Cytokine Growth Factor Rev. 2019 Feb;45:1-8. doi: 10.1016/j.cytogfr.2018.12.002. Epub 2018 Dec 12. Cytokine Growth Factor Rev. 2019. PMID: 30563755 Review.
Studies in recent years have identified a pivotal role of the cytokine IL-23 in the pathogenesis of inflammatory bowel diseases (IBD: Crohn´s disease, ulcerative colitis) and colitis-associated colon cancer. ...Consistently, neutralizing antibod …
Studies in recent years have identified a pivotal role of the cytokine IL-23 in the pathogenesis of inflammatory bowel disease …
Can IL-23 be a good target for ulcerative colitis?
Allocca M, Furfaro F, Fiorino G, Gilardi D, D'Alessio S, Danese S. Allocca M, et al. Best Pract Res Clin Gastroenterol. 2018 Feb-Apr;32-33:95-102. doi: 10.1016/j.bpg.2018.05.016. Epub 2018 May 23. Best Pract Res Clin Gastroenterol. 2018. PMID: 30060945 Review.
A considerable percentage of patients with ulcerative colitis (UC) do not respond to therapies, including anti-tumor necrosis factor (TNF) drugs and vedolizumab, or lose response over time. ...Increased levels of interleukin (IL)-23 and T helper …
A considerable percentage of patients with ulcerative colitis (UC) do not respond to therapies, including anti-tumor necrosis …
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, DenmarkSpecial Reporting on:• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• Real-World Analyses of Patients With IBD Treated With VedolizumabPLUS Meeting Abstract Summaries With Expert Commentary by: Edward V. Loftus Jr, MDProfessor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota.
[No authors listed] [No authors listed] Gastroenterol Hepatol (N Y). 2019 May;15(5 Suppl 2):1-24. Gastroenterol Hepatol (N Y). 2019. PMID: 31632213 Free PMC article. No abstract available.
Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
Wong U, Cross RK. Wong U, et al. Expert Opin Investig Drugs. 2019 May;28(5):473-479. doi: 10.1080/13543784.2019.1597053. Epub 2019 Mar 26. Expert Opin Investig Drugs. 2019. PMID: 30884245 Review.
INTRODUCTION: Blockade of interleukin (IL)-12 and IL-23 is a novel therapeutic target for inflammatory bowel disease (IBD). The monoclonal antibody targeting the shared p40 subunit of IL-12 and IL23, namely ustekinumab, has been approved for Cro …
INTRODUCTION: Blockade of interleukin (IL)-12 and IL-23 is a novel therapeutic target for inflammatory bowel dis …
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M, Morgan-Cox M, Laskowski J, Schmitz J, D'Haens GR. Sandborn WJ, et al. Gastroenterology. 2020 Feb;158(3):537-549.e10. doi: 10.1053/j.gastro.2019.08.043. Epub 2019 Sep 4. Gastroenterology. 2020. PMID: 31493397 Free article. Clinical Trial.
BACKGROUND & AIMS: Interleukin 23 contributes to the pathogenesis of ulcerative colitis (UC). We investigated the effects of mirikizumab, a monoclonal antibody against the p19 subunit of interleukin 23, in a phase 2 study of patients …
BACKGROUND & AIMS: Interleukin 23 contributes to the pathogenesis of ulcerative colitis (UC). We investigate …
Risankizumab: First Global Approval.
McKeage K, Duggan S. McKeage K, et al. Drugs. 2019 Jun;79(8):893-900. doi: 10.1007/s40265-019-01136-7. Drugs. 2019. PMID: 31098898 Review.
Risankizumab (Skyrizi(®)), a humanised IgG monoclonal antibody that targets the p19 subunit of IL-23, was developed by AbbVie in collaboration with Boehringer Ingelheim for the treatment of immunological and inflammatory disorders. ...Phase 2 and 3 clinical evaluati …
Risankizumab (Skyrizi(®)), a humanised IgG monoclonal antibody that targets the p19 subunit of IL-23, was developed by AbbVie …
Adverse events in IBD therapy: the 2018 update.
Quezada SM, McLean LP, Cross RK. Quezada SM, et al. Expert Rev Gastroenterol Hepatol. 2018 Dec;12(12):1183-1191. doi: 10.1080/17474124.2018.1545574. Expert Rev Gastroenterol Hepatol. 2018. PMID: 30791788 Review.
Crohn's disease and ulcerative colitis affect an increasing number of patients, and utilization of immune suppressant and biologic therapies is also increasing. ...Areas covered: This review provides an updated discussion on adverse events associated with immunomodu …
Crohn's disease and ulcerative colitis affect an increasing number of patients, and utilization of immune suppressant and biol …
New treatment options for inflammatory bowel diseases.
Verstockt B, Ferrante M, Vermeire S, Van Assche G. Verstockt B, et al. J Gastroenterol. 2018 May;53(5):585-590. doi: 10.1007/s00535-018-1449-z. Epub 2018 Mar 19. J Gastroenterol. 2018. PMID: 29556726 Free PMC article. Review.
Also, more selective anti-IL23 agents (anti-p19) have shown efficacy and are being further developed, in contrast to agents inhibiting IL-17 downstream which have failed in clinical trials despite their clear efficacy in psoriasis (Verstockt et al. in Expert Opin Biol Ther …
Also, more selective anti-IL23 agents (anti-p19) have shown efficacy and are being further developed, in contrast to agents inhibiting IL
269 results
Jump to page
Feedback